Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Margaret A. Lindorfer; Adrian Wiestner; Clive S. Zent; Ronald P. Taylor

doi:10.4161/onci.20368

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Margaret A. Lindorfer, Adrian Wiestner, Clive S. Zent, Ronald P. Taylor

Hematology

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Compelling evidence indicates type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune efector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more efective.

Original language	English (US)
Pages (from-to)	959-961
Number of pages	3
Journal	OncoImmunology
Volume	1
Issue number	6
DOIs	https://doi.org/10.4161/onci.20368
State	Published - 2012

Keywords

CD20 mAbs
Immunomonitoring
Therapeutic antibodies
Therapeutic trials
Trogocytosis

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.4161/onci.20368

Cite this

@article{98123c5da4274dee812c2224f4d4e238,

title = "Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?",

abstract = "Compelling evidence indicates type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune efector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more efective.",

keywords = "CD20 mAbs, Immunomonitoring, Therapeutic antibodies, Therapeutic trials, Trogocytosis",

author = "Lindorfer, {Margaret A.} and Adrian Wiestner and Zent, {Clive S.} and Taylor, {Ronald P.}",

year = "2012",

doi = "10.4161/onci.20368",

language = "English (US)",

volume = "1",

pages = "959--961",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "6",

}

TY - JOUR

T1 - Monoclonal antibody (mAb)-based cancer therapy

T2 - Is it time to reevaluate dosing strategies?

AU - Lindorfer, Margaret A.

AU - Wiestner, Adrian

AU - Zent, Clive S.

AU - Taylor, Ronald P.

PY - 2012

Y1 - 2012

N2 - Compelling evidence indicates type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune efector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more efective.

AB - Compelling evidence indicates type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune efector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more efective.

KW - CD20 mAbs

KW - Immunomonitoring

KW - Therapeutic antibodies

KW - Therapeutic trials

KW - Trogocytosis

UR - http://www.scopus.com/inward/record.url?scp=84880983195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880983195&partnerID=8YFLogxK

U2 - 10.4161/onci.20368

DO - 10.4161/onci.20368

M3 - Article

AN - SCOPUS:84880983195

SN - 2162-4011

VL - 1

SP - 959

EP - 961

JO - OncoImmunology

JF - OncoImmunology

IS - 6

ER -

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this